© 2002 by European Society of Cardiology
TASK FORCE ON SUDDEN CARDIAC DEATH, EUROPEAN SOCIETY OF CARDIOLOGY
Summary of Recommendations
The European Society of Cardiology has convened a Task Force on Sudden Cardiac Death in order to provide a comprehensive, educational document on this important topic. The main document has been published in the European Heart Journal in August 2001[1].
The Task Force has now summarized the most important clinical issues on sudden cardiac death and provided tables with recommendations for risk stratification and for prophylaxis of sudden cardiac death.
The present recommendations are specifically intended to encourage the development and revision of national guidelines on prevention of sudden cardiac death.
The common challenge for cardiologists, physicians of other medical specialties and health professionals throughout Europe is to realize the potential for sudden cardiac death prevention and to contribute to public health efforts to reduce its burden.
Key Words: Cardiac arrest, sudden death, arrhythmias
Correspondence: Silvia G. Priori, MD, PhD, FESC, Chairman Task Force on Sudden Cardiac Death of the European Society of Cardiology, Fondazione Salvatore Maugeri, University of Pavia, Via Ferrata 8, 27100 Pavia, Italy. E-mail: spriori{at}fsm.it
[1] Priori SG, Aliot E, Blomstrom-Lundqvist C. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374–1450.
[2] Myerburg RJ and Castellanos A. Cardiac arrest and sudden cardiac death. In Braunwald E (Ed.). Heart disease: a textbook of cardiovascular medicine 1997; New York WB Saunders Publishing Co pp. 742–779.
[3] Hinkle LE and Thaler HT. Clinical classification of cardiac death. Circulation 1982; 65: 457–464.
[4] Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17: 1390–1403.
[5] Becker LB, Smith DW, Rhodes KV. Incidence of cardiac arrest: a neglected factor in evaluating survival rates. Ann Emerg Med 1993; 22: 86–91.[CrossRef][Web of Science][Medline]
[6] Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231–1248.
[7] Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500–1505.[Abstract]
[8] Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 1992; 81:(1 Suppl) I2–I10.
[9] Gillum RF. Sudden coronary death in the United States: 1980–1985. Circulation 1989; 79: 756–765.
[10] McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829–833.[CrossRef][Web of Science][Medline]
[11] Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99: 1978–1983.
[12] Shaper AG, Wannamethee G, Macfarlane PW, Walker M. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 1993; 70: 49–55.
[13] Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995; 91: 1749–1756.
[14] Stevenson WG and Ridker PM. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA 1996; 276: 481–485.
[15] Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270–276.[Abstract]
[16] Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era GISSI-2 results. Circulation 1993; 87: 312–322.
[17] Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882–1890.
[18] Andresen D, Steinbeck G, Bruggemann T. Can the MADIT results be applied to myocardial infarction patients at hospital discharge? J Am Coll Cardiol 1998; 31:(suppl A) 308 (Abstract).
[19] Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933–1940.
[20] Malik M, Kulakowski P, Odemuyiwa O, et al. Effect of thrombolytic therapy on the predictive value of signal-averaged electrocardiography after acute myocardial infarction. Am J Cardiol 1992; 70: 21–25.[CrossRef][Web of Science][Medline]
[21] Zuanetti G, Neilson JM, Latini T, Santoro E, Maggioni AP, Ewing DJ. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 1996; 94: 432–436.
[22] Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993; 88: 180–185.
[23] Andresen D, Steinbeck G, Bruggemann T. Risk stratification following myocardial infarction in the thrombolytic era: a two-step strategy using noninvasive and invasive methods. J Am Coll Cardiol 1999; 33: 131–138.
[24] de Chillou C, Sadoul N, Bizeau O, et al. Prognostic value of thrombolysis, coronary artery patency, signal-averaged electrocardiography, left ventricular ejection fraction, and Holter electrocardiographic monitoring for life-threatening ventricular arrhythmia after a first acute myocardial infarction. Am J Cardiol 1997; 80: 852–858.[CrossRef][Web of Science][Medline]
[25] Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 1996; 17: 43–63.
[26] Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97: 2202–2212.
[27] Ziesche S, Rector ST, Cohn JN. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. J Card Fail 1995; 1: 127–132.[CrossRef][Medline]
[28] Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–310.[Abstract]
[29] E.ect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293–302.[Abstract]
[30] E.ect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–2007.[CrossRef][Web of Science][Medline]
[31] Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction— evidence from clinical trials. N Engl J Med 1996; 335: 1660–1667.
[32] Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598–604.
[33] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 708–717.
[34] LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.
[35] Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311–322.[CrossRef][Web of Science][Medline]
[36] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1381–1389.[CrossRef][Web of Science][Medline]
[37] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357.
[38] Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol 1993; 72: 280–287.[CrossRef][Web of Science][Medline]
[39] A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics vs Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576–1583.
[40] Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297–1302.
[41] Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748–754.
[42] Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with life-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667–674.[CrossRef][Web of Science][Medline]
[43] Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349: 675–682.[CrossRef][Web of Science][Medline]
[44] Buxton AE, Marchlinski FE, Flores BT, Miller JM, Doherty JU, Josephson ME. Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiological study. Circulation 1987; 75: 1178–1185.
[45] Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death; revisited in a large non-referral-based patients population. Circulation 2000; 102: 858–864.
[46] Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982; 65: 1388–1394.
[47] Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212–2218.
[48] Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365–373.
[49] McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412–416.
[50] Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997; 30: 1512–1520.[Abstract]
[51] Link MS, Wang PJ, Haugh CJ, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol 1997; 1: 41–48.[CrossRef][Medline]
[52] Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903–908.[CrossRef][Web of Science][Medline]
[53] Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999; 33: 1964–1970.
[54] Steinberg J, Ehlert F, Cannon D. Dilated cardiomyopathy vs coronary artery disease in patients with VT/VF: differences in presentation and outcome in the arrhythmics versus implantable defibrillators (AVID) registry. Circulation 1997; 96: (I-715-A).
[55] Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991; 84: 1136–1144.
[56] Schwartz PJ, Priori SG, Napolitano C. The Long QT Syndrome. In Zipes DP and Jalife J (Eds.). Cardiac Electrophysiology. From Cell to Bedside 2000; Philadelphia WB Saunders Co pp. 587–615.
[57] Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998; 339: 960–965.
[58] Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616–623.
[59] Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998; 97: 457–460.
[60] Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000; 102: 2509–2515.
[61] Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512–1519.
[62] Martinez-Rubio A, Schwammenthal Y, Schwammenthal E, et al. Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term follow-up. Circulation 1997; 96: 500–508.
[63] Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262–2270.
[64] Boudoulas H, Schaal SF, Stang JM, Fontana ME, Kolibash AJ, Wooley CF. Mitral valve prolapse: cardiac arrest with long-term survival. Int J Cardiol 1990; 26: 37–44.[CrossRef][Web of Science][Medline]
[65] Campbell RW, Godman MG, Fiddler GI, Marquis RM, Julian DG. Ventricular arrhythmias in syndrome of balloon deformity of mitral valve. Definition of possible high risk group. Br Heart J 1976; 38: 1053–1057.
[66] Liberthson RR, Dinsmore RE, Fallon JT. Aberrant coronary artery origin from the aorta. Report of 18 patients, review of literature and delineation of natural history and management. Circulation 1979; 59: 748–754.
[67] Click RL, Holmes DR, Vlietstra RE, Kosinski AS, Kronmal RA. Anomalous coronary arteries: location, degree of atherosclerosis and effect on survival — a report from the Coronary Artery Surgery Study. J Am Coll Cardiol 1989; 13: 531–537.[Abstract]
[68] Desseigne P, Tabib A, Loire R. Myocardial bridging on the left anterior descending coronary artery and sudden death. Apropos of 19 cases with autopsy. Arch Mal Coeur Vaiss 1991; 84: 511–516.[Web of Science][Medline]
[69] Tio RA, Van Gelder IC, Boonstra PW, Crijns HJ. Myocardial bridging in a survivor of sudden cardiac near-death: role of intracoronary doppler flow measurements and angiography during dobutamine stress in the clinical evaluation. Heart 1997; 77: 280–282.
[70] Zipes DP, DiMarco JP, Gillett PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 1995; 26: 555–573.[CrossRef][Web of Science][Medline]
[71] Bayes DL, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151–159.[CrossRef][Web of Science][Medline]
[72] Denes P, Dhingra RC, Wu D, Wyndham CR, Leon F, Rosen KM. Sudden death in patients with chronic bifascicular block. Arch Intern Med 1997; 137: 1005–1010.
[73] Strasberg B, Amat YL, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular nodal block. Circulation 1981; 63: 1043–1049.
[74] Edhag O and Swahn A. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers. A long-term follow-up study of 101 patients. Acta Med Scand 1976; 200: 457–463.[Web of Science][Medline]
[75] Pelliccia A, Maron BJ, Culasso F, et al. Athlete's heart syndrome revisited: prevalence and clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000; 102: 278–284.
[76] Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994; 24: 880–885.[Web of Science][Medline]
[77] Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21: 1216–1231.
[78] Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med 2000; 343: 1206–1209.
[79] American Heart Association in collaboration with the International Liaison Committee on Resuscitation International Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, A concensus on seizure, Resuscitation, 2000, 48, 1, 488, Circulation, 2000, 102, 1, 384.
[80] Monsieurs KG, Handley AJ, Bossaert LL. European Resuscitation Council Guidelines 2000 for Automated External Defibrillation. Resuscitation 2001; 48: 207–209.[CrossRef][Web of Science][Medline]
[81] de Latorre F, Nolan J, Robertson C, Chamberlain D, Baskett P. European Resuscitation Council Guidelines 2000 for Advanced Life Support. Resuscitation 2001; 48: 211–221.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Cosentino, L. Rydén, P. Francia, and L. G. Mellbin CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Eckardt, G&#x.;n. Breithardt, and S. Hohnloser CHAPTER 30 Ventricular Tachycardia and Sudden Cardiac Death ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Byrne, O. Constant, Y. Smyth, G. Callagy, P. Nash, K. Daly, and J. Crowley Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland Eur. Heart J., June 1, 2008; 29(11): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boriani, R. Ricci, T. Toselli, R. Ferrari, A. Branzi, and M. Santini Implantable cardioverter defibrillators: from evidence of trials to clinical practice Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I66 - I73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antzelevitch, G. D. Pollevick, J. M. Cordeiro, O. Casis, M. C. Sanguinetti, Y. Aizawa, A. Guerchicoff, R. Pfeiffer, A. Oliva, B. Wollnik, et al. Loss-of-Function Mutations in the Cardiac Calcium Channel Underlie a New Clinical Entity Characterized by ST-Segment Elevation, Short QT Intervals, and Sudden Cardiac Death Circulation, January 30, 2007; 115(4): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]
|
|
|
|
 |
|
 L Eckardt, G Breithardt, and P Kirchhof Approach to wide complex tachycardias in patients without structural heart disease. Heart, May 1, 2006; 92(5): 704 - 711. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ladich, R. Virmani, and A. Burke Sudden Cardiac Death not Related to Coronary Atherosclerosis Toxicol Pathol, January 1, 2006; 34(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Beery The Genetics of Cardiac Arrhythmias Biol Res Nurs, April 1, 2005; 6(4): 249 - 261. [Abstract] [PDF]
|
|
|
|
|
|
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology Eur. Heart J., February 2, 2005; 26(4): 384 - 416. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, B. R. Chaitman, M. J. Ackerman, A. Bayes de Luna, D. Corrado, J. E. Crosson, B. J. Deal, D. J. Driscoll, N.A. M. Estes III, C. G. S. Araujo, et al. Recommendations for Physical Activity and Recreational Sports Participation for Young Patients With Genetic Cardiovascular Diseases Circulation, June 8, 2004; 109(22): 2807 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, J. A Camm, R. Cappato, S. M Cobbe, C. Di Mario, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology Eur. Heart J., January 1, 2003; 24(1): 13 - 15. [Full Text] [PDF]
|
|
|
|
|
|
E. Moric, E. Herbert, M. Trusz-Gluza, A. Filipecki, U. Mazurek, and T. Wilczok The implications of genetic mutations in the sodium channel gene (SCN5A) Europace, January 1, 2003; 5(4): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||